Literature DB >> 29433389

Phytotherapeutic Activities of Sanguisorba officinalis and its Chemical Constituents: A Review.

Eungyeong Jang1,2, Kyung-Soo Inn3, Young Pyo Jang4,5, Kyung-Tae Lee4,6, Jang-Hoon Lee1.   

Abstract

Sanguisorba officinalis Linne (S. officinalis, Rosaceae) has been used as a medicinal plant for the treatment of burns, hematemesis, melena, intestinal infections, and dermatitis for a long time in China, Korea, and Japan. The therapeutic efficacy of this herb is intimately associated with its anti-oxidant, anti-inflammatory, antiviral, antifungal, hemostatic, and anticancer activities. Its root contains triterpenoid saponins (zigyuglycoside I: C[Formula: see text]H[Formula: see text]O[Formula: see text] and ziyuglycoside II: C[Formula: see text]H[Formula: see text]O8) and tannins (sanguiin H-6: C[Formula: see text]H[Formula: see text]O[Formula: see text]). It has been recently revealed that these active constituents of S. officinalis possess antiwrinkle properties without cytotoxicity. They also have anticancer effects by inducing apoptosis and cell cycle arrest. Moreover, they can inhibit proliferative tumorigenesis. The underlying mechanism involved in the pharmacological actions of these active constituents is mainly related to p38 MAPK signaling. Although various studies have reported its therapeutic activities and major chemical components, review articles that extensively organize various properties of S. officinalis and its major constituents are still scarce. Taken together, the objective of this paper is to provide overall pharmacological and phytochemical profiles of S. officinalis and its constituents (including ziyuglycoside I, ziyuglycoside II, and sanguiin H-6), and their potential roles in clinical applications for the treatment of inflammatory diseases, bleeding disorders, and cancer.

Entities:  

Keywords:  Review; Sanguiin H-6; Sanguisorba officinalis; Ziyuglycoside I; Ziyuglycoside II

Mesh:

Substances:

Year:  2018        PMID: 29433389     DOI: 10.1142/S0192415X18500155

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  13 in total

Review 1.  Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2020-05-28       Impact factor: 15.470

2.  Effect of Sanguisorba minor on scopolamine-induced memory loss in rat: involvement of oxidative stress and acetylcholinesterase.

Authors:  Zeinab Hosseini; Fatemeh Mansouritorghabeh; Faezeh Sadat Hosseini Kakhki; Mahmoud Hosseini; Hassan Rakhshandeh; Azar Hosseini; Maede Hasanpour; Mehrdad Iranshahi; Arezoo Rajabian
Journal:  Metab Brain Dis       Date:  2022-01-04       Impact factor: 3.584

3.  Sanguisorba officinalis L. derived from herbal medicine prevents intestinal inflammation by inducing autophagy in macrophages.

Authors:  Asuka Yasueda; Hisako Kayama; Michiko Murohashi; Junichi Nishimura; Koji Wakame; Ken-Ichi Komatsu; Takayuki Ogino; Norikatsu Miyoshi; Hidekazu Takahashi; Mamoru Uemura; Chu Matsuda; Toru Kitagawa; Kiyoshi Takeda; Toshinori Ito; Yuichiro Doki; Hidetoshi Eguchi; Shigeomi Shimizu; Tsunekazu Mizushima
Journal:  Sci Rep       Date:  2020-06-19       Impact factor: 4.379

4.  A tannin compound from Sanguisorba officinalis blocks Wnt/β-catenin signaling pathway and induces apoptosis of colorectal cancer cells.

Authors:  Wa Li; Chun-Juan Yang; Li-Qian Wang; Juan Wu; Cong Dai; Yue-Mei Yuan; George Q Li; Mei-Cun Yao
Journal:  Chin Med       Date:  2019-05-31       Impact factor: 5.455

5.  Antibacterial activity and synergy of antibiotics with sanguisorbigenin isolated from Sanguisorba officinalis L. against methicillin-resistant Staphylococcus aureus.

Authors:  S Wang; J Luo; X-Q Liu; O-H Kang; D-Y Kwon
Journal:  Lett Appl Microbiol       Date:  2021-01-08       Impact factor: 2.858

6.  In vitro anti-bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection.

Authors:  Xue Shen; Weijia Zhang; Chang Peng; Jiahui Yan; Pengting Chen; Cheng Jiang; Yuemei Yuan; Donglian Chen; Weixing Zhu; Meicun Yao
Journal:  Chin Med       Date:  2021-04-17       Impact factor: 5.455

7.  Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review).

Authors:  Yong Ji; Jian Lv; Di Sun; Yufeng Huang
Journal:  Int J Mol Med       Date:  2021-10-29       Impact factor: 4.101

8.  Wound-Healing Potential of Rhoifolin-Rich Fraction Isolated from Sanguisorba officinalis Roots Supported by Enhancing Re-Epithelization, Angiogenesis, Anti-Inflammatory, and Antimicrobial Effects.

Authors:  Walaa A Negm; Aya H El-Kadem; Engy Elekhnawy; Nashwah G M Attallah; Gadah Abdulaziz Al-Hamoud; Thanaa A El-Masry; Ahmed Zayed
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-31

9.  A Bioactive Compound from Sanguisorba officinalis L. Inhibits Cell Proliferation and Induces Cell Death in 5-Fluorouracil-Sensitive/Resistant Colorectal Cancer Cells.

Authors:  Weijia Zhang; Chang Peng; Xue Shen; Yuemei Yuan; Wei Zhang; Chunjuan Yang; Meicun Yao
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

Review 10.  Lamiaceae Essential Oils, Phytochemical Profile, Antioxidant, and Biological Activities.

Authors:  Luiz Renan Ramos da Silva; Oberdan Oliveira Ferreira; Jorddy Nevez Cruz; Celeste de Jesus Pereira Franco; Tainá Oliveira Dos Anjos; Marcia Moraes Cascaes; Wanessa Almeida da Costa; Eloisa Helena de Aguiar Andrade; Mozaniel Santana de Oliveira
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.